September is Sepsis Awareness Month, a reminder of the urgent need to improve how we understand, detect, and treat this life-threatening condition. This week’s Friday at Five, brought to you by Prenosis, highlights the groundbreaking innovation of Sepsis ImmunoScore™. Here are five things you should know.
Sepsis occurs when a person has an overactive response to an infection, and accounts for one in every three hospital fatalities in the U.S., with an estimated 1.7 million American adults developing sepsis each year. Even when patients survive a sepsis episode, the disease can have catastrophic and often permanent consequences on their quality of life after discharge.
Sepsis ImmunoScoreTM, developed by Prenosis, addresses the critical challenge of sepsis diagnosis and prediction. It was name a TIME Best Invention of 2024 and an honoree in Fast Company’s 2025 World Changing Ideas Awards.
FDA Authorization
Received FDA De Novo marketing authorization in April 2024 as the first and only FDA-authorized AI diagnostic tool for sepsis.
Risk Scoring
Holistically evaluates a patient’s biological status to output a risk score and place the patient into one of four discrete risk categories, providing both diagnostic and predictive information.
EHR Integration
Integrates directly into a hospital’s EHR system and is embedded in the clinical workflow without the need for an additional equipment.
Sepsis Early Warning Assistant
Works alongside early warning systems to assist providers in identifying patients at highest risk for sepsis or progression to sepsis within the next 24 hours.
True Clinician-AI Partnership
Displays how each patient’s parameters were used to calculate their sepsis score, critical in building trust with clinicians and enabling a true clinician-AI partnership.
